Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
727 Topline safety and efficacy update of SUPLEXA-101, a first-in-human, single agent study of SUPLEXA therapeutic cells in 28 patients with metastatic solid tumours
Compose a Response to This Article
Other responses
No responses have been published for this article.
